Antibiotics

It is a macrocyclic lipid antibiotic produced by the strain of Str. sp. HC34. In vitro it is cytotoxic to human leukemia HL-60 cells and human colon cancer Co-LO205 cells with IC50 (μg/mL) of 0.12 and 0.19, respectively.

It is a depsipeptide antibiotic produced by the strain of Streptomyces sp. M1982-63F1. It has activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 1.56-3.13 μg/mL.

It is a peptide antibiotic produced by the strain of Str. puniceus 1314-5 and Str. floridae A5014. It has broad-spectrum antibacterial and strong anti-mycobacterium effect. 1-10 μg/mL of Viomycin can inhibit the growth of most tuberculosis bacilli, the main effect is to inhibit the protein synthesis of bacteria, but bacteria are prone to develop drug resistance. In clinical application, it is only used as a second-line drug to treat tuberculosis.

It is produced by the strain of Str. sp. CH 41. It can inhibit the growth of murine leukemia cell P388 with IC50 of 5.8 ng/mL, and it can also inhibit KB human multi-squamous cell carcinoma cells with IC50 of 6.4 ng/mL.

It is produced by the strain of Str. sp. CH 41. It can inhibit the growth of murine leukemia cell P388 with IC50 of 2.8 ng/mL, and it can also inhibit KB human multi-squamous cell carcinoma cells with IC50 of 1.9 ng/mL.

It is a depsipeptide antibiotic produced by the strain of Str. virginiae and Str. virginiae var. sp. It has anti-gram-positive bacteria and mycobacterium effects, and the antibacterial activity of component M of Virginiamycin against cocci is stronger than component S, while the activity is stronger than component M.

It is a depsipeptide antibiotic produced by the strain of Str. virginiae and Str. virginiae var. sp. It has anti-gram-positive bacteria and mycobacterium effects, and the antibacterial activity of component M of Virginiamycin against cocci is stronger than component S, while the activity is stronger than component M.

It is a quinoline aromatic antibiotic produced by the strain of Pen. viridicatum, Pen. cyclopium SM-72 and Pen. puberulum. It has anti-gram-positive bacteria and mycobacteria effects.

It is a steroidal antibiotic produced by the strain of Gliocladium virens. It has anti-fungal and gram-positive bacterial effects.

It is a steroidal antibiotic produced by the strain of Gliocladium virens. It has anti-fungal and gram-positive bacterial effects.

It is a viridomycin antibiotic produced by the strain of Streptomyces sp. K96-0188. It has weak insecticidal and nematocidal activity. It also has weak activity against Piricularia oryzae and Acholeplasma laidlawii.

It is produced by the strain of Streptomyces sp. TP-A0597. It has anti-staphylococcus aureus, bacillus subtilis, proteus bizarre and cryptococcus neoformans activity with MIC (μg/mL) of 12.5, 25.0, 0.39 and 20.0, respectively.

It is produced by the strain of Streptomyces sp. TP-A0597. It has anti-staphylococcus aureus, bacillus subtilis, proteus bizarre and cryptococcus neoformans activity, but its antibacterial activity is lower than Watasemycin A.

It is a cyclopentane antibiotic produced by the strain of Str. xanthocidicus. It has weak effect against gram-negative bacteria.

It is produced by the strain of Penicillum simplicissimum IFO5762. It has anti-gram-positive bacteria activity, it can inhibit Bacillus subtilis and methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.78-1.56 μg/mL. It also has anti-yeast-like fungal activity, and it can inhibit Saccharomyces cerevisiae, Candida albicans and Cryptococcus neoformans with MIC of 3.13-25 μg/mL. It also has weak cytotoxicity to U937 cells with IC50 of 35 μg/mL.

It is an antifungal antibiotic produced by the strain of Streptomyces sp. TP-A0356. Its anti-fungal activity against Aspergillus fumigatus, Aspergillus flavus, Aspergillus Niger, Candida albicans and Cryptococcus neoformans is stronger than Amphotericin B and Etraconazole (MIC is 0.0039-0.0156 μg/mL). It also has strong cytotoxicity to P388, HeLa, HEL and other tumor cells (IC50 is 0.01-0.33 μg/mL).

Zygosporin D is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of 0.4 μg/mL. It has anti-tumor and anti-inflammatory properties.

Zygosporin E is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of 0.4 μg/mL. It has anti-tumor and anti-inflammatory properties.

Zygosporin F is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of >10 μg/mL. It has anti-tumor and anti-inflammatory properties.

Zygosporin G is produced by the strain of Zygosporium masonii MFC-612 and Zygosporium mycophylum MFC-702. It is cytotoxic to HeLa cells with ED50 of 0.68 μg/mL. It has anti-tumor and anti-inflammatory properties.